Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Hannes Kehm"'
Autor:
Aaron Rodriguez Ehrenfried, Stefan Zens, Laura Steffens, Hannes Kehm, Alina Paul, Claudia Lauenstein, Michael Volkmar, Isabel Poschke, Zibo Meng, Rienk Offringa
Publikováno v:
Bio-Protocol, Vol 14, Iss 8 (2024)
The advent of single-cell RNA sequencing (scRNAseq) has enabled in-depth gene expression analysis of several thousand cells isolated from tissues. We recently reported the application of scRNAseq toward the dissection of the tumor-infiltrating T-cell
Externí odkaz:
https://doaj.org/article/80169e7abb4d4422805f14f9da771b21
Autor:
Brian C. Avanzino, Kirthana Prabhakar, Pranjali Dalvi, Sharon Hartstein, Hannes Kehm, Aarti Balasubramani, Andrew A. Boudreau, Ben Buelow, Karen Chang, Laura M. Davison, Suhasini Iyer, Vidyut Kalwit, Kristin Lewis Wilson, Harbani K. Malik-Chaudhry, Will Pierson, Geovanni Pineda, Udaya S. Rangaswamy, Sowmya Saiganesh, Ute Schellenberger, Harshad S. Ugamraj, Rodolfovan D. Yabut, Roland Buelow, Jocelyn Chapman, Nathan D. Trinklein, Katherine E. Harris
Publikováno v:
OncoImmunology, Vol 11, Iss 1 (2022)
The use of T-cell engagers (TCEs) to treat solid tumors is challenging, and several have been limited by narrow therapeutic windows due to substantial on-target, off-tumor toxicities due to the expression of low levels of target antigens on healthy t
Externí odkaz:
https://doaj.org/article/9e96f15bb0a54d7bb137adf3be604c3c
Autor:
Brian C. Avanzino, Kirthana Prabhakar, Pranjali Dalvi, Sharon Hartstein, Hannes Kehm, Aarti Balasubramani, Andrew A. Boudreau, Ben Buelow, Karen Chang, Laura M. Davison, Suhasini Iyer, Vidyut Kalwit, Harbani Malik-Chaudhry, Will Pierson, Geovanni Pineda, Udaya S. Rangaswamy, Sowmya Saiganesh, Ute Schellenberger, Harshad S. Ugamraj, Roland Buelow, Jocelyn Chapman, Nathan D. Trinklein, Katherine E. Harris
Publikováno v:
Cancer Research. 82:6244-6244
The use of T cell engagers (TCEs) to treat solid tumors in humans is challenging, and several have been limited by narrow therapeutic windows due to substantial toxicity. Dose-limiting toxicities of TCEs include cytokine release syndrome (CRS) and on
Autor:
Steven A. Carr, Simon Köpff, Hannes Kehm, Michael Gütschow, Deepak Mani, Jan Krönke, Namrata D. Udeshi, Christian Steinebach, Stefanie Lindner
Publikováno v:
ACS Chemical Biology. 13:2771-2782
The immunomodulatory drugs (IMiDs) thalidomide, lenalidomide, and pomalidomide, all approved for the treatment of multiple myeloma, induce targeted ubiquitination and degradation of Ikaros (IKZF1) and Aiolos (IKZF3) via the cereblon (CRBN) E3 ubiquit
Autor:
Stefanie Lindner, Hannes Kehm, Martin Mangold, Christian Steinebach, Michael Gütschow, Jan Krönke
Publikováno v:
Journal of Visualized Experiments.
The immunomodulatory drugs (IMiDs) thalidomide and its analogs, lenalidomide and pomalidomide, all FDA approved drugs for the treatment of multiple myeloma, induce ubiquitination and degradation of the lymphoid transcription factors Ikaros (IKZF1) an
Autor:
Michael Gütschow, Michaela Reichenzeller, Lan Phuong Vu, Simon Köpff, Karl G. Wagner, Corinna Weiler, Hannes Kehm, Christian Steinebach, Stefanie Lindner, Jan Krönke, Álvaro López Mármol
Publikováno v:
Chemical communications (Cambridge, England). 55(12)
Small-molecule heterobifunctional degraders can effectively control protein levels and are useful research tools. We assembled proteolysis targeting chimeras (PROTACs) from a cereblon (CRBN) and a von-Hippel-Lindau (VHL) ligase ligand and demonstrate
Autor:
Aarti Balasubramani, Ute Schellenberger, Harshad Ugamraj, Suhasini Iyer, Nathan D. Trinklein, Laura Davison, Brian Avanzino, Sharon Hartstein, Ben Buelow, Andrew Boudreau, Sowmya Saiganesh, Priya Ganesan, Duy Pham, Udaya Rangaswamy, Kirthana Prabhakar, Hannes Kehm, Harbani K. Malik-Chaudhry, Katherine E. Harris
Publikováno v:
Journal of Clinical Oncology. 38:e18050-e18050
e18050 Background: Ovarian Cancer (OvCa) is the leading cause of gynecologic cancer mortality in women. Since the introduction of platinum-based chemotherapy there has been little change in the prognosis of OvCa patients, with < 30% overall survival
Autor:
Jan Krönke, Steven A. Carr, Namrata D. Udeshi, Hannes Kehm, Stefanie Lindner, Michael Gütschow, Christian Steinebach, Deepak Mani, Simon Köpff
Publikováno v:
Blood. 132:260-260
The immunomodulatory drugs (IMiDs) thalidomide, lenalidomide, and pomalidomide are all approved for the treatment of multiple myeloma. IMiDs bind cereblon (CRBN), a substrate adaptor for the CRL4 E3 ubiquitin ligase (CRL4CRBN). In multiple myeloma, I